Navigation Links
Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
Date:10/23/2010

ent of CDI. These studies were designed to evaluate safety and compare the response to treatment in subjects during and after a 10-day course of therapy. The primary endpoint was non-inferiority compared to Vancocin in clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication.  If cured, subjects were monitored for a subsequent four-week period to evaluate recurrence, which was a secondary endpoint.  Global cure, also a secondary endpoint, was defined as patients who were cured and did not have a recurrence during this subsequent four-week period. In both of these studies, fidaxomicin achieved its primary endpoint of non-inferiority compared to Vancocin.  Fidaxomicin was also statistically superior to Vancocin in recurrence rate, reducing CDI recurrences by 47% and in global cure rate. Fidaxomicin was well tolerated in both studies.

About FidaxomicinFidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in rapid killing of C. difficile. The narrow-spectrum profile of fidaxomicin eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, seriously disrupt the flora. Fidaxomicin facilitates the early return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence.

About Clostridium difficile Infection (CDI)Clostridium difficile infection (CDI), commonly referred to as c-diff., has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cau
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to the article published ... of the Pasadena courthouse was contained and extinguished by the city’s fire department before it ... the building at the time of the fire, and it was a fire alarm system ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries and ... cakes with custom designs, making life just a little bit sweeter for newlyweds. ... for each customer who orders one. , The bakery provides a full line of ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the ... in pursuit of a visionary image that goes beyond the boundaries of fertility medicine. ... IVF has reached extraordinary heights with dependable patient support, affordable treatments, unending hope, and ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... LINTHICUM, MD. The AUA is pleased to announce their ... Cancer. Each year, more than 60,000 people are diagnosed ... number of risk factors, including cigarette smoking and exposure ... in 1999 and the report issued today is an ...
... universal hepatitis B immunisation means that most UK citizens ... in this weeks BMJ. , The UK is one ... routinely immunise children against hepatitis B, despite a call ... of vaccine prevention programmes by 1997, writes Andrew Pollard, ...
... binge drinking in the UK rise, doctors in this weeks ... attended hospital with lower abdominal pain. , Although rare, this ... alcohol intake. , Alcohol misuse is costing the NHS up ... by alcohol dependence or poisoning and 22,000 premature deaths each ...
... settlement as ,the ... right thing to do, HOUSTON, Nov. ... agreement with pharmaceutical giant,Merck & Co. Inc. (NYSE: MRK ) that ... over Vioxx, the company,s,controversial pain medication. (Photo: http://www.newscom.com/cgi-bin/prnh/20060623/DAF008 ) ...
... Provides Preliminary Information on Recapitalizations, Asset Sales and ... Anticipated Pre-Tax Charges ... on Accounting Restatement, MCLEAN, Va., Nov. 9 Sunrise Senior Living,Inc. ... the quarter ended September 30, 2007. The Company also,provided preliminary information on ...
... Client Development Officer, SOMERSET, N.J., Nov. 9 ... it has created a new Client Development,and Integration team. ... was recently,promoted to Chief Client Development Officer. The ... across the company,s segments to identify new opportunities to,serve ...
Cached Medicine News:Health News:AUA releases new guidelines on non-muscle invasive bladder cancer 2Health News:Most UK citizens susceptible to hepatitis B infection 2Health News:The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc. 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 3Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 4Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 5Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 6Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 7Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 8Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 9Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 10Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 11Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 12Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 13Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: